Literature DB >> 7854006

Interactions of MDL 29,311 and probucol metabolites with cholesteryl esters.

L R McLean1, N Brake, K A Hagaman.   

Abstract

The hypothesis that the efficacy of hydrophobic antioxidants in animal models of atherogenesis may, in part, be related to physical effects on cholesteryl esters in cells was probed with analogs and metabolites of probucol. The interactions of an effective bis-thiomethane analog (MDL 29,311) and selected metabolites of probucol with cholesteryl oleate were examined by differential scanning calorimetry and polarized light microscopy. Like probucol, MDL 29,311 and the bisphenol metabolite decrease the liquid-crystalline phase transition enthalpy of cholesteryl oleate with increasing concentrations. At 20 mol%, no transition is detectable. By contrast, the spiroquinone metabolite of probucol and the diphenoquinone metabolite common to both molecules have minimal effects on the liquid-crystalline transitions of cholesteryl oleate. At 20 mol%, neither compound has as great an effect as 1 mol% MDL 29,311. Consistent with their effects on dry cholesteryl oleate, MDL 29,311 and the bisphenol metabolite convert lipid inclusions in cells supplemented with cholesterol to an isotropic physical state similar to that observed with probucol. The number of anisotropic inclusions in the cells decreases with increasing concentration in the medium in the range of 50 to 250 micrograms/mL. In cells fed with the spiroquinone or diphenoquinone metabolites, the lipid inclusions are liquid-crystalline and resemble those observed with cholesterol-fed controls. These data are interpreted in terms of a model in which hydrophobic antioxidants closely related to probucol disrupt the packing of cellular cholesteryl esters.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7854006     DOI: 10.1007/bf02536248

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  9 in total

Review 1.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

2.  Physical-chemical basis of lipid deposition in atherosclerosis.

Authors:  D M Small; G G Shipley
Journal:  Science       Date:  1974-07-19       Impact factor: 47.728

3.  George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry.

Authors:  D M Small
Journal:  Arteriosclerosis       Date:  1988 Mar-Apr

4.  Probucol reduces the rate of association of apolipoprotein C-III with dimyristoylphosphatidylcholine.

Authors:  L R McLean; K A Hagaman
Journal:  Biochim Biophys Acta       Date:  1988-04-15

5.  Effect of lipid physical state on the rate of peroxidation of liposomes.

Authors:  L R McLean; K A Hagaman
Journal:  Free Radic Biol Med       Date:  1992       Impact factor: 7.376

6.  Modulation of the physical state of cellular cholesteryl esters by 4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (probucol).

Authors:  L R McLean; C E Thomas; B Weintraub; K A Hagaman
Journal:  J Biol Chem       Date:  1992-06-15       Impact factor: 5.157

7.  Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies.

Authors:  M Aviram; G Dankner; U Cogan; E Hochgraf; J G Brook
Journal:  Metabolism       Date:  1992-03       Impact factor: 8.694

8.  Cellular cholesteryl ester clearance. Relationship to the physical state of cholesteryl ester inclusions.

Authors:  J M Glick; S J Adelman; M C Phillips; G H Rothblat
Journal:  J Biol Chem       Date:  1983-11-25       Impact factor: 5.157

9.  Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol.

Authors:  S J Mao; M T Yates; R A Parker; E M Chi; R L Jackson
Journal:  Arterioscler Thromb       Date:  1991 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.